Acasti Pharma Files 8-K
Ticker: GRCE · Form: 8-K · Filed: Sep 25, 2024 · CIK: 1444192
| Field | Detail |
|---|---|
| Company | Acasti Pharma INC. (GRCE) |
| Form Type | 8-K |
| Filed Date | Sep 25, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
Related Tickers: ACST
TL;DR
ACST filed an 8-K on 9/25/24. No specifics yet, but check for updates.
AI Summary
Acasti Pharma Inc. filed an 8-K on September 25, 2024, reporting other events and financial statements. The company, incorporated in Quebec with principal executive offices in Princeton, New Jersey, has a fiscal year end of March 31. The filing does not detail specific events or financial figures but serves as a notification of these items.
Why It Matters
This filing indicates that Acasti Pharma Inc. is providing updates or disclosures to the SEC, which could contain important information for investors regarding company events or financial health.
Risk Assessment
Risk Level: low — The filing is a standard procedural disclosure and does not contain specific negative or positive news that would immediately impact risk.
Key Numbers
- 0331 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
Key Players & Entities
- Acasti Pharma Inc. (company) — Registrant
- September 25, 2024 (date) — Date of earliest event reported
- Princeton, New Jersey (location) — Address of Principal Executive Offices
- 001-35776 (other) — SEC File Number
FAQ
What specific 'Other Events' are being reported by Acasti Pharma Inc. in this 8-K filing?
The provided text of the 8-K filing does not specify the details of the 'Other Events' being reported, only that this item is being addressed.
What is the significance of the 'Financial Statements and Exhibits' being filed?
The filing indicates that financial statements and exhibits are being submitted, which typically provide detailed financial performance and supporting documentation, though the specifics are not detailed in this excerpt.
When was the earliest event reported in this Form 8-K?
The earliest event reported in this Form 8-K was on September 25, 2024.
Where are Acasti Pharma Inc.'s principal executive offices located?
Acasti Pharma Inc.'s principal executive offices are located at 103 Carnegie Center, Suite 300, Princeton, New Jersey, 08540.
What is Acasti Pharma Inc.'s SEC File Number?
Acasti Pharma Inc.'s SEC File Number is 001-35776.
Filing Stats: 410 words · 2 min read · ~1 pages · Grade level 11.6 · Accepted 2024-09-25 08:00:34
Filing Documents
- ef20036277_8k.htm (8-K) — 31KB
- ef20036277_ex99-1.htm (EX-99.1) — 19KB
- image00001.jpg (GRAPHIC) — 3KB
- 0001140361-24-041832.txt ( ) — 193KB
- acst-20240925.xsd (EX-101.SCH) — 4KB
- acst-20240925_lab.xml (EX-101.LAB) — 21KB
- acst-20240925_pre.xml (EX-101.PRE) — 16KB
- ef20036277_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On September 25, 2024, the Company issued a press release announcing the Company's pivotal Phase 3 STRIVE-ON safety trial has completed enrollment. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01
Item 9.01 Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release, dated September 25, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ACASTI PHARMA INC. Date: September 25, 2024 By: /s/ Prashant Kohli Prashant Kohli Chief Executive Officer